Table 3.
Number and prevalence of selected RTK gene fusions among 50 644 thyroid FNA samples by Bethesda category
| RTK gene | AUS/FLUS (III) | FN/SFN (IV) | SFM (V) | Malignant (VI) |
|---|---|---|---|---|
| ALK | 29 (0.07%) | 22 (0.23%) | 3 (0.36%) | 0 (0.00%) |
| BRAF | 88 (0.22%) | 47 (0.50%) | 15 (1.79%) | 13 (1.52%) |
| NTRK1 | 16 (0.04%) | 8 (0.08%) | 2 (0.24%) | 2 (0.23%) |
| NTRK3 | 126 (0.32%) | 67 (0.71%) | 21 (2.51%) | 15 (1.75%) |
| RET | 86 (0.22%) | 40 (0.42%) | 40 (4.78%) | 24 (2.81%) |
| Any | 345 (0.87%) | 184 (1.94%) | 81 (9.68%) | 54 (6.32%) |
Table 1 reports the total number of samples in each Bethesda category and the Bethesda category abbreviations.
Abbreviation: RTK, receptor tyrosine kinase.